

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/115150 A1

(43) International Publication Date
29 June 2023 (29.06.2023)

(51) International Patent Classification:

<i>C07D 471/04</i> (2006.01)	<i>A61P 21/00</i> (2006.01)
<i>A61K 31/437</i> (2006.01)	<i>A61P 25/00</i> (2006.01)
<i>A61K 31/4545</i> (2006.01)	<i>A61P 29/00</i> (2006.01)
<i>A61K 31/513</i> (2006.01)	<i>A61P 31/00</i> (2006.01)
<i>A61K 47/55</i> (2017.01)	<i>A61P 35/00</i> (2006.01)
<i>A61P 1/00</i> (2006.01)	<i>A61P 37/00</i> (2006.01)
<i>A61P 11/00</i> (2006.01)	<i>A61P 43/00</i> (2006.01)
<i>A61P 19/00</i> (2006.01)	<i>A61P 9/00</i> (2006.01)

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2022/051576

(22) International Filing Date:

22 December 2022 (22.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021904198 22 December 2021 (22.12.2021) AU

(71) Applicant: **ANAXIS PHARMA PTY LTD** [AU/AU];
Bio21 Institute, 30 Flemington Road, Parkville, Victoria
3052 (AU).

(72) Inventors: **GARNIER, Jean-Marc Daniel**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU).
GARDNER, Christopher; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU). **LESSENE, Guillaume Laurent**; c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

(74) Agent: **FPA PATENT ATTORNEYS PTY LTD**; Level 19, South Tower, 80 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

(54) Title: BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS

(57) Abstract: This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis and/or inhibit and/or degrade MLKL.

WO 2023/115150 A1